anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
BACKGROUND AND OBJECTIVES: Rapid detection of cerebrospinal fluid (CSF) leaks is vital for patient recovery after spinal surgery. However, distinguishing CSF-specific transferrin (TF) from serum TF using lateral flow immunoassays (LFI) is challenging due to their structural similarities. This study aims to develop a novel point-of-care diagnostic assay for precise CSF leak detection by quantifying total TF in both CSF and serum.
METHODS: Capitalizing on the substantial 100-fold difference in TF concentrations between CSF and serum, we designed a diagnostic platform based on the well-known "hook effect" resulting from excessive analyte presence. Clinical samples from 37 patients were meticulously tested using the novel LFI sensor, alongside immunofixation as a reference standard.
RESULTS: The hook effect-based LFI sensor exhibited outstanding performance, successfully discriminating positive clinical CSF samples from negative ones with remarkable statistical significance (positive vs negative t -test; P = 1.36E-05). This novel sensor achieved an impressive 100% sensitivity and 100% specificity in CSF leak detection, demonstrating its robust diagnostic capabilities.
CONCLUSION: In conclusion, our study introduces a rapid, highly specific, and sensitive point-of-care test for CSF leak detection, harnessing the distinctive TF concentration profile in CSF compared with serum. This novel hook effect-based LFI sensor holds great promise for improving patient outcomes in the context of spinal surgery and postsurgical recovery. Its ease of use and reliability make it a valuable tool in clinical practice, ensuring timely and accurate CSF leak detection to enhance patient care.
Pullulan sulphates and their salts are new cpds. and are useful for treating gastric ulcers and have low anti-coagulant activity, so they can be used in cases where haemorrhage is present; they can also be used as food additives, ion exchangers and sizing agents. The pullulan moiety pref. has a mol. wt. of 10,000-5,000,000 and the sulphate pref. contains 5-20 wt. % S. The salts can include the Na, K, Mg, Ca, NH4 and Al salts and mixts. thereof.
Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
INTRODUCTION: We hypothesized that multidisciplinary, proactive electronic consultation (MPE) could overcome barriers to prescribing guideline-directed medical therapies (GDMTs) for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).
RESEARCH DESIGN AND METHODS: We conducted an efficacy-implementation pilot study of MPE for T2D and CKD for primary care provider (PCP)-patient dyads at an academic health system. MPE included (1) a dashboard to identify patients without a prescription for sodium-glucose cotransporter-2 inhibitors (SGLT2i) and without a maximum dose prescription for renin-angiotensin-aldosterone system inhibitors (RAASi), (2) a multidisciplinary team of specialists to provide recommendations using e-consult templates, and (3) a workflow to deliver timely e-consult recommendations to PCPs. In-depth interviews were conducted with PCPs and specialists to assess feasibility, acceptability, and appropriateness of MPE and were analyzed using an iterative qualitative analysis approach to identify major themes. Prescription data were extracted from the electronic health record to assess preliminary effectiveness to increase GDMT.
RESULTS: 20 PCPs agreed to participate, 18 PCPs received MPEs for one of their patients with T2D and CKD, and 16 PCPs and 2 specialists were interviewed. Major themes were as follows: appropriateness of prioritization of GDMT for T2D and CKD, acceptability of the content of the recommendations, PCP characteristics impact experience with MPE, acceptability and appropriateness of multidisciplinary collaboration, feasibility of MPE to overcome patient-specific barriers to GDMT, and appropriateness of workflow. At 6 months postbaseline, 7/18 (39%) patients were newly prescribed an SGLT2i, and 7/18 (39%) patients were either newly prescribed or had increased dose of RAASi.
CONCLUSIONS: MPE was an acceptable and appropriate health system strategy to identify and address gaps in GDMT among patients with T2D and CKD. Adopting MPE could enhance GDMT, though PCPs raised feasibility concerns which could be improved with program enhancements, including follow-up e-consults for reinforcement, and administrative support for navigating system-level barriers.
BACKGROUND: Older adults have complex medical needs that causes increased use of resources at the emergency department (ED). The prevalence of non-specific complaint (NSC) as a chief-complaint in the ED is common among older adults and is not prioritized even though possibly having worse clinical outcome. The objective was to study hospital admission and mortality for older adults visiting the ED with NSC compared to specific complaints such as dyspnea, chest pain and abdominal pain.
METHODS: A retrospective observational study of older adults visiting the ED with NSC and specific complaints; dyspnea, chest pain and abdominal pain was performed. Chief-complaint were collected from electronic medical records. Fatigue, confusion, non-specific complaints, generalized weakness and risk of falling were defined as non-specific complaint (NSC) when registered as chief-complaint at the ED. Admission rate and 30-days mortality were the primary outcomes.
RESULTS: A total of 4927 patients were included in the study based on chief-complaint; patients with chest pain 1599 (32%), dyspnea 1343 (27%), abdominal pain 1460 (30%) and NSC 525 (11%). Patients with dyspnea and NSC had the highest hospital admission rate 79% vs 70% compared to patients with chest pain (63%) and abdominal pain (61%) (p =  < 0.001). Patients with NSC had a mean LOS 4.7 h at the ED which was significantly higher compared to chest pain, dyspnea and abdominal pain. Mean bed-days for the whole population was 4.2 days compared to patients with NSC who had a mean LOS of 5.6 days. NSC and dyspnea were both associated with the highest 30-day mortality.
CONCLUSION: Older patients who present with NSC at the ED are associated with a high risk for admission and 30-days mortality. In addition, patients with NSC have a longer LOS at the ED, a high admission rate and the highest number of bed-days once admitted. This study indicates that ED staff should be more vigilant when an elderly patient presents with NSC at the ED. Further studies and guidelines are needed to improve the management of these individuals.
Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
Patient journey mapping, a novel method to visualize all the interactions a patient might have with the health system, is increasingly being adopted by the healthcare industry to identify challenges patients face, with the goal of improving health outcomes. However, patient journey maps are often used internally within pharma companies and are not published widely. Here, I conducted in-depth interviews with eight Indian patients/caregivers dealing with chronic and/or serious conditions; seven of the interviewees were living in India and spoke entirely from the perspective of the Indian health system, whereas one spoke from his experience of living in India, Ireland, and the UK. Using insights from these interviews, drawing on my own experience as a patient living with a rare disease and multiple comorbidities, and seeking feedback from several international patient advocates and industry professionals, I constructed a detailed map visualizing the collective journey of patients with serious/chronic conditions. Apart from showing the different stages in the patient journey, the map visualizes the associated stress levels, pain points (issues leading to a negative experience), emotions, and information-seeking behavior. One key insight that emerges is that along with a range of highly variable emotions patients experience, stress is a consistent factor throughout the patient journey. In many cases, the stress is caused or exacerbated by factors that can be avoided, such as long wait times, procedural hassles, inadequate or inaccurate information, and lack of empathy in interactions with healthcare professionals. The frustrations patients experience stem from a mix of underlying practical/tangible and emotional/aspirational needs. I have discussed these needs at length and provided suggestions for changes that could be implemented in the health system to meet these needs better. While my analysis presented here is generally framed from the context of the Indian health system, and some points discussed might have nuances in other health systems, the themes and insights provided are relevant to all patients and their journey, anywhere in the world. Pharmaceutical industry professionals, healthcare providers, and policymakers may benefit from these insights and may apply them to make strategic decisions and changes in their approach, with the goal of improving patient experience and health outcomes globally.
The overarching goal of this study is to advance research on family-based prevention of negative child outcomes for reintegrating Operation Enduring Freedom/Operation Iraqi Freedom personnel by evaluating different formats of a parenting program, After Deployment, Adaptive Parenting Tools (ADAPT). The ADAPT program is based upon the Parent Management Training-Oregon Model/PMTO, but adapted for military deployed families. The investigators will examine which of three delivery formats of ADAPT is most effective at reducing youth risk behaviors associated with negative childhood outcomes by improving parenting, child, and parent adjustment. There is a clear intent to benefit all subjects in this study (except surveyed teachers), including children.

Combat deployment and related challenges are family stressors, associated with more negative parent-child interactions, ineffective and coercive parenting practices and lower levels of parenting satisfaction. Disrupted parenting practices are well-known predictors of risk for child adjustment difficulties that are precursors to youth substance use, including behavior problems, school failure, deviant peer association, and depression . These child adjustment problems can contribute to continuing parental stress, increasing parental distress, and further disrupting parenting.
Patients undergo LCT over 2-4 weeks. If LCT cannot be used to treat primary disease sites, patients also undergo IMRT or 3DCRT over 3-5 weeks. Within 2 weeks after completion of radiation therapy, patients receive chemotherapy as in Arm 1. Patients may possibly undergo surgery.
The invention discloses a jujube-stone sealwort and a preparation method thereof, wherein the jujube-stone sealwort is prepared by 1000 parts of sealwort, 100 parts of yellow wine, 5 parts of cellulase, 1 part of amylase, 100 parts of pitted red date, 250 parts of walnut kernel, 6 parts of dictyophora powder, 250 parts of white sugar, 150 parts of maltose, 15 parts of honey and a proper amount of water. Slicing rhizoma Polygonati, performing enzymolysis and enzyme deactivation, oven drying, and pulverizing to obtain rhizoma Polygonati powder. The honey water is uniformly sprayed on the rhizoma polygonati powder for standby. And (4) drying the core-removed red dates and the walnut kernels for later use. Adding water into white sugar, maltose and Dictyophora Indusiata powder, decocting until the water content is required for making sugar, adding Mel and rhizoma Polygonati powder, mixing, adding crisp fructus Jujubae and semen Juglandis, mixing, cooling, and slicing to obtain the final product. The jujube-walnut-rhizoma polygonati prepared by the method reserves beneficial components of the jujube-walnut-rhizoma polygonati to human health. The identification of different groups and batches is consistent: the food preparation mode and the food material compatibility method are innovative, and the taste and the adaptive crowd have wide market prospects.
Before use, the needle will be removed from the refrigerator and kept on the nurse's table. When the temperature of the needle reaches 0-2 °C, the patient will be cannulated.
N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.
Due to modern lifestyle factors such as high work pressure, stressful routines, and environmental pollution, there has been a significant decline in sperm quality among men, potentially leading to infertility. In response, various supplements have emerged claiming to enhance sperm quality. This prospective investigation aims to determine the efficacy of a new supplement in improving sperm quality among patients with poor sperm quality. The study will enroll 50 patients undergoing semen analysis at our reproductive center, administering the supplement over a three-month treatment period to those identified with poor sperm quality. Subsequent semen analysis will be conducted, alongside assessments of sperm mitochondrial metabolic function before and after supplement administration. Sexual function and aging symptoms will also be evaluated using the International Index of Erectile Function (IIEF-5) and the Aging Males Symptoms Scale (AMS) before and after the supplementation period. The study aims to compare differences in semen analysis, sperm mitochondrial metabolic function, sexual function, and aging symptoms before and after supplementation.
OBJECTIVES: This study aims to retrospectively analyze the clinical features of Stanford type A acute aortic dissection (TAAAD) based on Sun's modified classification, and to investigate whether the Sun's modified classification can be used to assess the risk of preoperative rupture.
METHODS: Clinical data was collected between January 2018 and June 2019. Data included patient demographics, history of disease, type of dissection according to the Sun's modified classification, time of onset, biochemical tests, and preoperative rupture.
RESULTS: A total of 387 patients with TAAAD who met the inclusion criteria of Sun's modified classification were included. There were more complex types, with 75, 151 and 140 patients in the type A1C, A2C and A3C groups, respectively. The age of the entire group of patients was 51.46 ± 12.65 years and 283 (73.1%) were male. The time from onset to the emergency room was 25.37 ± 30.78 h. There were a few cases of TAAAD combined with stroke, pericardial effusion, pleural effusion, and lower extremity and organ ischemia in the complex type group. The white blood cell count (WBC), neutrophil count (NEC) and blood amylase differed significantly between the groups. Three independent risk factors for preoperative rupture were identified: neutrophil count, blood potassium ion level, and platelet count. Binary logistic regression analysis showed that the Sun's modified classification could not be used to assess the risk of preoperative rupture in TAAAD.
CONCLUSION: TAAAD was classified as the complex type in most patients. WBC, NEC and blood amylase were significantly different between the groups. NEC and serum potassium ion level were independent risk factors for preoperative rupture of TAAAD, while platelet count was its protective factor. More samples are needed to determine whether Sun's modified classification can be used to evaluate the risk of preoperative rupture.
PROBLEM TO BE SOLVED: To obtain a quinuclidine derivative-containing pharmaceutical having an excellent and selectively antagonistic action on muscarine M3 and useful for prevention or treatment of nervous pollakisuria, neurogenic bladder, nocturnal enuresis and the like by including a specific quinuclidine derivative. SOLUTION: This pharmaceutical is obtained by including a quinuclidine derivative of formula I (a ring A is e.g. a substitutable aryl or cycloalkyl; X is a single bond or methylene; R is e.g. a halogen or OH; (l) is 0 or 1; (m) is 0 to 3; and (n) is 1 or 2), its salt or its quaternary ammonium salt (pref. e.g. 3-quinuclidyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate). A compound of formula I is obtained by reacting a compound of formula II (Q1 is an eliminating group) with a compound of III in an inert solvent under room temperature to heating temperature. In oral administration, the dosage per adult is 0.01 to 100 mg/kg per day and it is administrated at one dose or dividedly at 2 to 4 doses.
<P>PROBLEM TO BE SOLVED: To provide an antibody specifically binding to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR, and an antigen-binding site thereof.  <P>SOLUTION: The human anti-IGF-IR antibody includes chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The isolated heavy and light chain immunoglobulin molecules derived from the anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules are also provided. Further, the method of making the anti-IGF-IR antibody, the pharmaceutical composition comprising these antibodies and the method of using the antibody and the composition thereof for diagnosis and treatment are provided. The gene therapy method uses nucleic acid molecules encoding the heavy and/or light chain immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The nonhuman transgenic animal expresses the nucleic acid.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PURPOSE: Pediatric severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections are usually mild and the mortality rates are low, but concerns have been raised about long-term symptoms that may resemble other postinfectious syndromes. Studies with robust control groups and high response rates have been few.
METHODS: We obtained identifiers for all 837 Icelandic children diagnosed with SARS-CoV-2 by PCR between March 2020 and June 2021 and contacted them by telephone. We asked about 10 physical and mental symptoms being present at least twice weekly for at least 2 months. Participants who reported symptoms were contacted again a year later. For each subject who completed the questionnaire, an age- and sex-matched comparator without SARS-CoV-2 infection was asked to complete the same questionnaire, and the risk difference was calculated.
RESULTS: Responses from 643 cases and 602 comparators were analyzed. Children who had been infected with SARS-CoV-2 were more likely to report one or more symptoms, except for anxiety/depression and sleep disturbances. Fatigue and loss of concentration were evidently more common in cases among teenagers (risk difference: 15%; 95% CI: 7-22% and 15%; 95% CI: 7-23%, respectively). At the second follow-up, close to a third of Long COVID cases had resolved but some participants had developed new persistent symptoms.
CONCLUSION: Symptoms of Long COVID in children are common and impact their quality of life. The importance of further unraveling the pathophysiology of acute and long-term symptoms following SARS-CoV-2 infection in children is vital as well as potential preventive measures.
Disclosed are probiotic compositions and related methods for detoxification of the recreational drug gamma-hydroxybutyric acid (GHB). In some aspects, provided herein is a recombinant bacterium comprising a nucleic acid comprising at least one nucleotide sequence encoding a GHB dehydrogenase (GHBDH) and at least one nucleotide sequence encoding a succinate-semialdehyde dehydrogenase (SSADH). In some embodiments, the recombinant bacterium is non-pathogenic. In some embodiments, the recombinant bacterium is a food-grade bacterium. In some embodiments, the recombinant bacterium is Bacillus subtilis, e.g., Bacillus subtilis strain PY79. In some embodiments, the GHB dehydrogenase (GHBDH) is derived from the bacterium. In some embodiments, the succinate-semialdehyde dehydrogenase (SSADH) is derived from the bacterium Agrobacterium tumefaciens C58.
Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as peripheral blood or apheresis derived mononuclear cells. The CD4+ and/or CD8+ T-cells are activated, genetically modified, and propagated in separate or isolated cultures with one or more cytokines, which support survival, engraftment and/or proliferation as well as promoting or inducing the retention of cell surface receptors such as CD62L, CD28, and/or CD27. Preferably, such cytokines may be IL2, IL7, IL21, or IL15. The CAR may be specific for CD19. Included herein are also methods of treatment, inhibition, amelioration or elimination of a cancer, particularly leukaemia, by administering one or more types of the genetically engineered T-cells to a subject.
A green tea vein toothpaste is provided to prevent decayed tooth, to clean foolery and to relieve pain of teeth or gingiva using a component of green tea. A green tea vein toothpaste includes 3-15 weight% of fiber particulate component of leaves of the green tea. The leaves of the green tea are collected, put into water and heated. The chlorophyll and cell formations are gone. Stem, petiole, and tough fibrous material component of vein are remained. After the leaves of the green tea are dried, the leaves of the green tea are made by making the leaves of the green tea into powders. A method for manufacturing the green tea vein toothpaste comprises step of: remaining the stem, the petiole, and the tough fibrous material component of the vein by putting the leaves of the green tea in water and heating the leaves of the green tea; drying a material of the fibrous material component; crushing the dried material; filtering the ground material; and manufacturing the filtered particle into toothpaste.
PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.